Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still's Disease.
Journal
European journal of rheumatology
ISSN: 2147-9720
Titre abrégé: Eur J Rheumatol
Pays: Turkey
ID NLM: 101656068
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
pubmed:
10
8
2022
medline:
10
8
2022
entrez:
9
8
2022
Statut:
ppublish
Résumé
Macrophage activation syndrome is the most frequent life-threatening complication of adult-onset Still's disease. This is a nearly fatal case of a young patient, which has been refractory to corticoste- roids, anakinra, tocilizumab, cyclosporine A, and etoposide, but eventually responded miraculously to salvage therapy with ruxolitinib. We review recent pertinent data related to the therapeutic value of ruxolitinib for macrophage activation syndrome triggered by adult-onset Still's disease.
Identifiants
pubmed: 35943464
doi: 10.5152/eurjrheum.2022.21064
pmc: PMC10089131
doi:
Types de publication
Journal Article
Langues
eng
Pagination
217-220Références
Ann Rheum Dis. 2020 Jun;79(6):842-844
pubmed: 32079571
Expert Rev Clin Immunol. 2018 May;14(5):351-365
pubmed: 29658384
Rheumatol Int. 2020 Apr;40(4):663-669
pubmed: 31367795
Blood. 2016 Mar 31;127(13):1666-75
pubmed: 26825707
Nat Rev Drug Discov. 2017 Dec 28;17(1):78
pubmed: 29282366
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
Blood. 2016 Jul 7;128(1):60-71
pubmed: 27222478
Blood. 2019 Jul 11;134(2):103-104
pubmed: 31296541
Ann Rheum Dis. 2018 Jun;77(6):840-847
pubmed: 29472362
Leukemia. 2015 Oct;29(10):2062-8
pubmed: 26228813
Haematologica. 2020 May;105(5):e210-e212
pubmed: 31515353
Lancet Haematol. 2019 Dec;6(12):e630-e637
pubmed: 31537486
J Cancer Res Clin Oncol. 2020 Nov;146(11):3063-3074
pubmed: 32617699
Rheumatology (Oxford). 2019 Apr 1;58(4):736-737
pubmed: 30590753
Blood. 2019 Jun 6;133(23):2465-2477
pubmed: 30992265
Blood. 2019 Jul 11;134(2):147-159
pubmed: 31015190
Autoimmun Rev. 2014 Nov;13(11):1149-59
pubmed: 25183244